Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

Manabu Soda, Young Lim Choi, Munehiro Enomoto et al. · Nature · 2007 · 5.4K citations

Oncology, Non-small-cell Lung Cancer, Eml4–alk Fusion Gene +11

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

Eunice L. Kwak, Yung‐Jue Bang, D. Ross Camidge et al. · New England Journal of Medicine · 2010 · 4.5K citations

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Klarisa Rikova, Ailan Guo, Qingfu Zeng et al. · Cell · 2007 · 2.3K citations · Full text

Oncology, Medicine, Global Survey +7

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

D. Ross Camidge, Yung‐Jue Bang, Eunice L. Kwak et al. · The Lancet Oncology · 2012 · 1.3K citations · Full text

Oncology, Medicine, Updated Results +10

An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms

Helen Y. Zou, Qiuhua Li, Joseph H. Lee et al. · Cancer Research · 2007 · 746 citations · Full text

Tumor Biology, C-met Kinase, Chemoprevention Strategy +15